1. Scrip
  2. >>New Products

Gilead Becomes Third To Market In Second-Line PBC, With Label Advantages

 
• By Joseph Haas

Gilead will make the case that Livdelzi is a better treatment option than Ocaliva or recently approved Iqirvo due to its ability to alleviate pruritus and reduce ALP levels.

FDA approved
Gilead is third to market in second-line PBC therapy with Livdelzi

Gilead Sciences, Inc. made a substantial bet on moving into a different kind of liver disease with its $4.3bn takeout in February of CymaBay Therapeutics, Inc., and that transaction is beginning to bear fruit with the US Food and Drug Administration approval on 14 August of Livdelzi (seladelpar) for second-line treatment of primary biliary cholangitis (PBC). In that setting, Livdelzi will compete against two second-line agents, Alfasigma S.p.A.’s Ocaliva (obeticholic acid), approved in 2016, and Ipsen SA/Genfit SA’s Iqirvo (elafibranor), which obtained FDA approval in June.

In an interview with Scrip, Gilead executive director of global medical affairs for liver diseases Carrie Frenette declined to offer...

More from New Products

Pipeline Watch: Ten Approvals And Seventeen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Defying Gravity: Five Drugs That Surpassed Their Sales Forecasts

 
• By Edwin Elmhirst

Many assets outperform their pre-launch sales predictions despite the frequent overestimation of forecasts within the industry. In this article, Scrip highlights several such assets and the factors that influenced their predictions.

Gilead’s Yeztugo Gets US Approval For Twice-Yearly PrEP

 
• By Alexandra Shimmings

The first twice-yearly option for HIV prevention has been approved by the US Food and Drug Administration in an advance that “brings us closer than ever to ending the HIV epidemic,” said CEO Daniel O’Day.

Pipeline Watch: Eight Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from Scrip

Novo And Lilly Lay Out Patient Segmentation Plans For Obesity Treatment

 
• By Andrew McConaghie

As competition heats up and the obesity market matures, the two frontrunners are tailoring their studies to the wants and needs of different patient groups.

Vertex Heralds ‘Unprecedented’ Zimislecel Type 1 Diabetes Data

 
• By Kevin Grogan

The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.

Pipeline Watch: Ten Approvals And Seventeen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.